So maybe I'm a cockeyed optimist, but I feel in my heart that we have a legitimate shot at EUA for CD-12 imminently (for the critical patient subgroup), and that the purpose of the 140 patient trial is to ultimately attain full FDA approval for the critical patient subgroup, which we will likely attain because of the modified primary endpoint.